12 April 2021 - New ICER pilot will incorporate more than 24 months of observational real world demographic, utilisation, and cost ...
8 April 2021 - Report will be subject of CTAF meeting in October 2021; draft scoping document open to public comment ...
5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially ...
17 March 2021 - A commonly-used analysis to determine a medicine's value is based on flawed methodologies that would diminish ...
15 March 2021 -Aurinia Pharmaceuticals today announced a favorable assessment regarding the cost-effectiveness and value of Lupkynis (voclosporin), based on ...
15 March 2021 - Report will be subject of New England CEPAC meeting in September 2021; draft scoping document open ...
12 March 2021 - The evidence suggests belimumab and voclosporin represent important new treatment options for lupus nephritis; there is ...
5 March 2021 - Independent appraisal committee determines the evidence is not adequate to demonstrate that roxadustat provides a net ...
2 March 2021 - The U.S. has never had a publicly funded, independent health technology assessment organisation to evaluate prescription drugs, ...
2 March 2021 - For bempedoic acid, independent appraisal committee votes that the evidence is not adequate to demonstrate a net ...
11 February 2021 - Many countries use independent review boards to balance innovation and profit. ...
11 February 2021 - Public comment period now open until March 11, 2021; Requests to make oral comment during public meeting ...
10 February 2021 - The ICER announced today it has extended its timeline for assessing the comparative clinical effectiveness and ...
9 February 2021 - As breakthrough drugs stream out of biopharmaceutical laboratories, how much they should cost and who will ...
28 January 2021 - Other than a proven ability to reduce the need for intravenous iron supplements, the evidence is insufficient ...